Aspire Pharma’s
Acquisition strengthens Aspire Pharma’s strategic portfolio
Acquisition Strengthens Aspire Pharma’s Strategic Portfolio
Aspire Pharma Ltd, a rapidly growing UK-based specialty generics business, today announces the acquisition of Charlwood Pharma Ltd, a privately owned company specialising in the research & development of niche generic medicines. The acquisition marks the culmination of a successful multi-year collaboration between the two organisations.
Charlwood brings to Aspire a robust pipeline of products spanning mental health, ear, nose and throat (ENT), cardiovascular and respiratory therapy areas - complementing Aspire’s existing portfolio and growth strategy.
Richard Condon, Aspire Pharma Chief Executive, said: “This acquisition not only strengthens our existing portfolio, but also stands as a testament to the value of long-term partnerships with Aspire, which deliver meaningful innovations that enhance patient care. Under the terms of this agreement, Aspire will assume full ownership of all intellectual property, which reinforces our ambitions for international expansion. This acquisition further demonstrates Aspire’s commitment to delivering quality, affordable medicines that support the highest levels of patient care, while offering true value to healthcare systems throughout the world.”
About Aspire Pharma
Aspire was established with a simple mission: To make a difference to the lives of patients through the development and supply of innovative products and medicines throughout the world. Aspire is present in the specialty, niche generics, branded generics, and medical device sectors. Aspire was majority acquired by an affiliate of H.I.G. Capital (“H.I.G.”) in 2021. For more information, go to: www.aspirepharma.com.
About H.I.G. Capital
H.I.G. Capital is a leading global alternative investment firm with $70 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Dallas, Los Angeles, New York, and San Francisco in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, and Dubai, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/value-added approach.
